Your blood cancer doesn't stand still. Pinpoint where you are with clonoSEQ®.
About MRD
MRD is one of the strongest predictors of outcomes in blood cancers
Minimal residual disease (MRD) refers to the small number of cancer cells that can stay in the body during and after treatment. Often, these cells are present at such low levels that they do not cause any physical signs or symptoms. They may be a sign that cancer is returning.[1,2]
Today, new treatments are helping patients like you live longer than ever before. Some patients may have such low levels of remaining cancer cells that not all tests can detect them. Therefore, your doctor needs highly sensitive options, like the clonoSEQ test, to help measure MRD and assess therapy responses over time.[1-5]
As one of the strongest predictors of outcomes in blood cancers, MRD status can help you and your doctor understand your prognosis and how it may change over time.[1] When your MRD status shifts, you may find that the course of your blood cancer journey changes as well.
Together, you and your healthcare team can keep a watchful eye on your MRD trends and use them to inform important decisions about your care.
Learn about how MRD testing can help patients like you plan for the future and move forward
Why clonoSEQ
Gain confidence in your future with clonoSEQ
clonoSEQ® (pronounced clo-no-seek) is the first and only FDA-cleared test that detects, counts, and tracks MRD in blood or bone marrow samples from patients with chronic lymphocytic leukemia (CLL) and bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL).[1]
With clonoSEQ, you and your doctors can:
Monitor
your cancer by assessing treatment response and detecting changes in disease[1]
Manage
decisions with an ongoing understanding of your long-term outcomes[1]
Move Forward
with confidence when planning for all of life’s moments[1]
Because clonoSEQ can detect one single cancer cell among a million healthy cells (provided sufficient sample material), you and your doctor can be confident you know if residual disease is present in your sample after each clonoSEQ test.[1]
From your clonoSEQ report, your doctor can determine whether your MRD status is positive (detectable disease) or negative (undetectable disease).
References to “cancer” on this webpage refer specifically to CLL, multiple myeloma, and B-ALL. References to “sample” refer to bone marrow or blood from patients with CLL and bone marrow from patients with multiple myeloma or B-ALL. Talk to your doctor about your options if you have another type of blood cancer and are interested in MRD testing.
A clonoSEQ Journey
Understanding the clonoSEQ Patient Journey
Can knowing your MRD status help you manage decisions along your cancer journey?
Monitoring MRD to detect changes in your disease can show how well your treatment is working. Knowing your MRD status, together with other clinical information, can help inform future decisions at key points in your care, such as:
Monitoring MRD to detect changes in your disease can show how well your treatment is working. Knowing your MRD status, together with other clinical information, can help inform future decisions at key points in your care, such as:
Monitoring MRD to detect changes in your disease can show how well your treatment is working. Knowing your MRD status, together with other clinical information, can help inform future decisions at key points in your care, such as:
If you have CLL, multiple myeloma, or B-ALL, talk with your doctor to begin tracking your MRD status with clonoSEQ today.
clonoSEQ Report
Understanding a clonoSEQ report
Adaptive Biotechnologies delivers a report summarizing your clonoSEQ MRD results to your doctor to review along with clinical examination, your medical history, and other test results and findings. Be sure to talk with your doctor about the optimal timing for clonoSEQ testing based on the type of blood cancer you have and your specific treatment plan.
clonoSEQ reports include the following information:
clonoSEQ MRD Status
A positive (+) result means residual disease was detected. A negative (-) result means residual disease was not detected. Each report will provide your updated MRD status.* You can gain valuable insights about your cancer regardless of whether you have a positive or negative result.
Talk with your doctor about your clonoSEQ MRD status to better understand what a positive or negative result means for you and your treatment plan. Setting a goal of MRD negativity may be right for some patients. Your doctor can help determine whether it is right for you.
*False positive or false negative results may occur for reasons including, but not limited to: contamination, technical, and/or biological factors.
MRD Level
This is the amount of cancer-related cells detected in your sample. This number shows how much disease is present in your sample at that point in time. Your doctor can help put this number into context based on your current phase of treatment and therapeutic goals.
MRD Trend
A simple graph will show any changes detected in your MRD level over time. Watching these changes will help you and your doctor better understand your response to treatment and track changes in your cancer over time.
Resources
Adaptive Assist™ Patient Support Program
Our commitment to supporting patient access
Adaptive Biotechnologies understands that each patient’s situation is unique. We are committed to providing guidance and support during each step of the insurance process.
How We Help:
Tailored support for different patient needs, including understanding coverage, navigating insurance, and individualized assistance
Learn more
Additional Resources
There are many organizations working to help patients and caregivers connect with others and learn about blood cancers, treatments, and diagnostic tools.
This page is intended for use by patients and caregivers of the United States.
clonoSEQ® is an FDA-cleared test used to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service.
clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
Citations
- clonoSEQ®. https://clonoseq.com/technical-summary. Seattle, WA: Adaptive Biotechnologies; 2020.
- Pulsipher M, et al. Blood. 2015;125(22):3501-8.
- Wood B, et al. Blood. 2018;131(12):1350-59.
- Perrot A, et al. Blood. 2018;132(23):2456-64.
- Thompson P, et al. Blood. 2019;134(22):1951-59.
- Sherrod A, et al. Bone Marrow Transplant. 2015;51:2-12.
- NCI Dictionary of Cancer Terms: Complete Remission. National Cancer Institute. Accessed November 17, 2017.
- Dimier N, et al. Blood. 2018;131(9):955-62.
- Munir T, et al. Blood. 2017;130(Suppl 1):3013.
- Molica S, et al. Clin Lymphoma Myeloma Leuk. 2019;19(7):423-30.
- Kater A, et al. Blood Adv. 2018;2(24):3566-71.
- Hillmen P, et al. J Clin Oncol. 2019;37(30):2722-29.
- Fraser G, et al. Leukemia. 2019;33(4):969-80.
- Martinez-Lopez J, et al. Blood Adv. 2020;4(14):3295-301.
- O’Dwyer M, et al. Blood Adv. 2019;3(12):1815-25.
- Voorhees P, et al. Blood. 2020;136(8):936-45.
- Mateos M, et al. Lancet. 2020;395(10218):132-41.
- Bahlis N, et al. Leukemia. 2020;34:1875-84.
- Berry DA, et al. JAMA Oncol. 2017;3(7):E1-9.
- Raff T, et al. Blood. 2007;109(3):910-5.